Center for Medical Mycology, Department of Dermatology, Case Western Reserve Universitygrid.67105.35, Cleveland, Ohio, USA.
Pfizer Inc., New York, New York, USA.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0054921. doi: 10.1128/AAC.00549-21.
Antifungal activity of anidulafungin, voriconazole, isavuconazole, and fluconazole in the treatment of Candida auris was determined and . MICs for anidulafungin, voriconazole, isavuconazole, fluconazole, and amphotericin B were 0.5, 1, >64, 0.25, and 4 μg/ml, respectively. Significant efficacy was observed in the anidulafungin- and voriconazole-treated groups in survival and reduction in kidney tissue fungal burden compared to that in the untreated group ( values of <0.001 and 0.044, respectively). Our data showed that anidulafungin and voriconazole had comparable efficacies against C. auris, whereas isavuconazole did not show significant activity.
测定了安尼拉fungin、伏立康唑、伊曲康唑和氟康唑治疗耳念珠菌的抗真菌活性，。安尼拉fungin、伏立康唑、伊曲康唑、氟康唑和两性霉素 B 的 MIC 分别为 0.5、1、>64、0.25 和 4μg/ml。与未治疗组相比，安尼拉fungin 和伏立康唑治疗组的存活率和肾脏组织真菌负荷均有显著改善（值分别为<0.001 和 0.044）。我们的数据表明，安尼拉fungin 和伏立康唑对耳念珠菌具有相当的疗效，而伊曲康唑则没有显著的活性。
